Resveratrol co-treatment attenuates the effects of HIV protease inhibitors on rat body weight and enhances cardiac mitochondrial respiration
Date
2017-01-20
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
Abstract
Since the early 1990s human immunodeficiency virus (HIV)/acquired immunodeficiency
syndrome (AIDS) emerged as a global health pandemic, with sub-Saharan Africa the hardest
hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief
to HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially
HIV protease inhibitors (PIs) are implicated in the onset of cardio-metabolic complications
such as type-2 diabetes and coronary heart disease. As there is a paucity of data
regarding suitable co-treatments within this context, this preclinical study investigated
whether resveratrol (RSV), aspirin (ASP) or vitamin C (VitC) co-treatment is able to blunt
side-effects in a rat model of chronic PI exposure (Lopinavir/Ritonavir treatment for 4
months). Body weights and weight gain, blood metabolite levels (total cholesterol, HDL,
LDL, triglycerides), echocardiography and cardiac mitochondrial respiration were assessed
in PI-treated rats ± various co-treatments. Our data reveal that PI treatment significantly lowered
body weight and cardiac respiratory function while no significant changes were found
for heart function and blood metabolite levels. Moreover, all co-treatments ameliorated the
PI-induced decrease in body weight after 4 months of PI treatment, while RSV co-treatment
enhanced cardiac mitochondrial respiratory capacity in PI-treated rats. This pilot study
therefore provides novel hypotheses regarding RSV co-treatment that should be further
assessed in greater detail.
Description
CITATION: Symington, B., Mapanga, R. F., Norton, G. R. & Essop, M. F. 2017. Resveratrol co-treatment attenuates the effects of HIV protease inhibitors on rat body weight and enhances cardiac mitochondrial respiration. PLoS ONE, 12(1):e0170344, doi:10.1371/journal.pone.0170344.
The original publication is available at http://journals.plos.org/plosone
The original publication is available at http://journals.plos.org/plosone
Keywords
Resveratrol, HIV infections -- Treatment, AIDS (Disease) -- Treatment
Citation
Symington, B., Mapanga, R. F., Norton, G. R. & Essop, M. F. 2017. Resveratrol co-treatment attenuates the effects of HIV protease inhibitors on rat body weight and enhances cardiac mitochondrial respiration. PLoS ONE, 12(1):e0170344, doi:10.1371/journal.pone.0170344.